Literature DB >> 24502832

Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Rohtesh S Mehta1, Antonio Di Stasi2, Chitra Hosing2, Nina Shah2, Katayoun Rezvani2, Amin Alousi2, Susan O'Brien2, William Wierda2, Michael Keating2, Elizabeth J Shpall2.   

Abstract

Entities:  

Keywords:  GVHD; Hepatitis; Refractory CLL

Mesh：

Substances：

Year:  2013        PMID： 24502832      PMCID： PMC4840930          DOI： 10.1016/j.clml.2013.12.013

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  29 in total

1.  Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.

Authors:  Cynthia L Toze; Chinmay B Dalal; Thomas J Nevill; Tanya L Gillan; Yasser R Abou Mourad; Michael J Barnett; Raewyn C Broady; Donna L Forrest; Donna E Hogge; Stephen H Nantel; Maryse M Power; Kevin W Song; Heather J Sutherland; Clayton A Smith; Sujaatha Narayanan; Sean S Young; Joseph M Connors; John D Shepherd
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

Review 2.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

3.  Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Authors:  Katja Sockel; Martin Bornhaeuser; Eva Mischak-Weissinger; Rudolf Trenschel; Martin Wermke; Christian Unzicker; Guido Kobbe; Jürgen Finke; Ulrich Germing; Brigitte Mohr; Jochen Greiner; Dietrich Beelen; Christian Thiede; Gerhard Ehninger; Uwe Platzbecker
Journal:  Haematologica       Date:  2012-09       Impact factor: 9.941

4.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

5.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

6.  Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years.

Authors:  Pankaj Malhotra; William J Hogan; Mark R Litzow; Michelle A Elliott; Dennis A Gastineau; Stephen M Ansell; Angela Dispenzieri; Morie A Gertz; Suzanne R Hayman; David J Inwards; Martha Q Lacy; Ivana N Micallef; Luis F Porrata; Ayalew Tefferi
Journal:  Leuk Lymphoma       Date:  2008-09

7.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Authors:  Constantine S Tam; Susan O'Brien; Susan Lerner; I Khouri; A Ferrajoli; S Faderl; M Browning; Apostolia M Tsimberidou; Hagop Kantarjian; William G Wierda
Journal:  Leuk Lymphoma       Date:  2007-10

8.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

9.  Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

Authors:  J R Brown; H T Kim; P Armand; C Cutler; D C Fisher; V Ho; J Koreth; J Ritz; C Wu; J H Antin; R J Soiffer; J G Gribben; E P Alyea
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528

10.  Lenalidomide in the treatment of chronic lymphocytic leukemia.

Authors:  Agostino Cortelezzi; Mariarita Sciumè; Gianluigi Reda
Journal:  Adv Hematol       Date:  2012-05-08
View more
  4 in total

1.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

2.  Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Authors:  Mauricette Michallet; Peter Dreger; Mohamad Sobh; Linda Koster; Jennifer Hoek; Ariane Boumendil; Christof Scheid; Christopher P Fox; Gerald Wulf; William Krüger; Michel van Gelder; Paolo Corradini; Domenico Russo; Jakob Passweg; Hélène Schoemans; Wolfgang Bethge; Nicolaas Schaap; Jan Cornelissen; Paul Browne; Nadira Durakovic; Lutz Muller; Silvia Montoto; Nicolaus Kroger; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

3.  Post-allograft pomalidomide and reversible hepatotoxicity.

Authors:  J M Pauff; R S Gonzalez; K P Sajnani; A Kassim; M Jagasia
Journal:  Bone Marrow Transplant       Date:  2014-06-23       Impact factor: 5.483

4.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.